Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients

被引：0
|
作者：
Cao, Lei [1 ]
Cao, Zhili [1 ]
Liu, Hongsheng [1 ]
Liang, Naixin [1 ]
Bing, Zhongxing [1 ]
Tian, Caijuan [2 ]
Li, Shanqing [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing 100730, Peoples R China
[2] Tianjin Marvelbio Technol Co Ltd, Tianjin Marvel Med Lab, Tianjin 300381, Peoples R China
来源：
CURRENT ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
non-small-cell lung cancer; immunotherapy; tumor mutation burden; microsatellite instability; programmed cell death protein-1; gene mutation; IMMUNE CHECKPOINT INHIBITORS; REDUCED FOLATE CARRIER; MICROSATELLITE INSTABILITY; SIGNALING PATHWAY; T-CELL; PD-L1; NSCLC; POLYMORPHISMS; RESISTANCE; THERAPIES;
D O I：
10.3390/curroncol29080451
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Microsatellite instability (MSI), high tumor mutation burden (TMB-H) and programmed cell death 1 ligand 1 (PD-L1) expression are hot biomarkers related to the improvement of immunotherapy response. Two cohorts of non-small-cell lung cancer (NSCLC) were collected and sequenced via targeted next-generation sequencing. Drug analysis was then performed on the shared genes using three different databases: Drugbank, DEPO and DRUGSURV. A total of 27 common genes were mutated in at least two groups of TMB-H-, MSI- and PD-L1-positive groups. AKT1, SMAD4, SCRIB and AXIN2 were severally involved in PI3K-activated, transforming growth factor beta (TGF-beta)-activated, Hippo-repressed and Wnt-repressed pathways. This study provides an understanding of the mutated genes related to the immunotherapy biomarkers of NSCLC.
引用
收藏
页码：5715 / 5730
页数：16
相关论文
共 50 条
  • [21] Recent advances in immunotherapy for non-small-cell lung cancer
    Suzuki, Hiroyuki
    Owada, Yuki
    Watanabe, Yuzuru
    Inoue, Takuya
    Fukuharav, Mitsuro
    Yamaura, Takumi
    Mutoh, Satoshi
    Okabe, Naoyuki
    Yaginuma, Hiroshi
    Hasegawa, Takeo
    Yonechi, Atsushi
    Ohsugi, Jun
    Hoshino, Mika
    Higuchi, Mitsunori
    Shio, Yutaka
    Gotoh, Mitsukazu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (02) : 352 - 357
  • [22] Targeted therapies and immunotherapy in non-small-cell lung cancer
    Cortinovis, D.
    Abbate, M.
    Bidoli, P.
    Capici, S.
    Canova, S.
    ECANCERMEDICALSCIENCE, 2016, 10
  • [23] Immunotherapy combinations emerging in non-small-cell lung cancer
    Chao, Yvonne L.
    Pecot, Chad V.
    IMMUNOTHERAPY, 2018, 10 (08) : 627 - 629
  • [24] Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
    Cascone, Tina
    Fradette, Jared
    Pradhan, Monika
    Gibbons, Don L.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2022, 12 (05):
  • [25] Quantifying the benefit of non-small-cell lung cancer immunotherapy
    Ludmir, Ethan B.
    Mccaw, Zachary R.
    Grossberg, Aaron J.
    Wei, Lee-jen
    Fuller, C. David
    LANCET, 2019, 394 (10212): : 1904 - 1904
  • [26] Perioperative immunotherapy for resectable non-small-cell lung cancer
    Xiaodong Yang
    Dongliang Bian
    Jie Yang
    Liang Duan
    Haifeng Wang
    Deping Zhao
    Gening Jiang
    Yuming Zhu
    Peng Zhang
    Clinical Cancer Bulletin, 3 (1):
  • [27] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
  • [28] Current status of immunotherapy for non-small-cell lung cancer
    Imbimbo, Martina
    Lo Russo, Giuseppe
    Blackhall, Fiona
    TUMORI JOURNAL, 2016, 102 (04): : 337 - 351
  • [29] Immunotherapy in non-small-cell lung cancer: a good start?
    Bogart, Jeffrey A.
    Gajra, Ajeet
    LANCET ONCOLOGY, 2014, 15 (01): : 5 - 6
  • [30] Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
    Chen, Lanyi Nora
    Wei, Alexander Z.
    Shu, Catherine A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345